GOLD D Patients in Primary Care: A Group Whose Clinical Outcomes Can Easily Be Improved

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21146

Enrollment

Registered

2015-11-10

Start date

2015-02-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD GOLD D

Interventions

Treatment in the integrated care system of Certe (AC Service) for 12 months

Eligibility

Inclusion criteria

Inclusion criteria: • Age > 40 (all patients) • Diagnosed COPD (work package 1) • Diagnosis compatible with GOLD D classification (work package 2)

Exclusion criteria

Exclusion criteria: • Asthma diagnosis, asthma/COPD overlap syndrome or other respiratory illnesses • Inability to complete questionnaires due to language or cognitive difficulties

Design outcomes

Primary

Measure	Time frame
WP1: - We aim to describe the baseline characteristics of GOLD D patients. WP2: -We aim to identify the difference in health status between baseline and final follow up at 12 months, as measured by the CCQ and CAT.	—

Secondary

Measure	Time frame
WP1: We will compare the baseline characteristics of GOLD D patients with those of GOLD group A, B, and C patients. • We will compare GOLD D patients as assessed using either CCQ ≥ 1 or CAT ≥ 10 criteria. • We will evaluate how representative the Certe AC Service patients are of the wider COPD population by comparing their characteristics with those of patients in the UNLOCK initiative. WP2: • We aim to identify the patient characteristics associated with changes in quality of life, thereby seeking to validate the known patient phenotypes, such as frequent exacerbators, patients with rapid decline in FEV1, patients with low body mass index, and those with poor exercise capacity. Gold D in primary care Version 3, 10th June 2015 12 of 28 • We will compare the following variables between the year preceding the study and the study period: o Differences in exacerbation rates; o Differences in health care costs; o Differences in medication use; and o Differences in patient characteristics between gold d and gold a, b and c patients. • Using data based on their usual care, we also aim to identify the characteristics of patients that change classification within the study period, as follows: o Those changing from GOLD D to another GOLD group (A, B, or C) versus those that remain unchanged, and; o Those changing from GOLD group A, B or C to another GOLD group versus those that remain unchanged.	—

Measure

Time frame

WP1: We will compare the baseline characteristics of GOLD D patients with those of GOLD group A, B, and C patients. • We will compare GOLD D patients as assessed using either CCQ ≥ 1 or CAT ≥ 10 criteria. • We will evaluate how representative the Certe AC Service patients are of the wider COPD population by comparing their characteristics with those of patients in the UNLOCK initiative. WP2: • We aim to identify the patient characteristics associated with changes in quality of life, thereby seeking to validate the known patient phenotypes, such as frequent exacerbators, patients with rapid decline in FEV1, patients with low body mass index, and those with poor exercise capacity. Gold D in primary care Version 3, 10th June 2015 12 of 28 • We will compare the following variables between the year preceding the study and the study period: o Differences in exacerbation rates; o Differences in health care costs; o Differences in medication use; and o Differences in patient characteristics between gold d and gold a, b and c patients. • Using data based on their usual care, we also aim to identify the characteristics of patients that change classification within the study period, as follows: o Those changing from GOLD D to another GOLD group (A, B, or C) versus those that remain unchanged, and; o Those changing from GOLD group A, B or C to another GOLD group versus those that remain unchanged.

—

Contacts

Public ContactC. Jong, de

P.O.Box 30.001

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)